BPGbio, Inc., a leading AI-powered biopharma company that focuses on oncology, neurology and rare diseases, today announced the commercial launch of the NAi (pronounced “nye”) Interrogative Biology® Platform, the company’s AI-powered platform technology for broad scale development and repurposing of drugs, identification of diagnostic biomarkers, and health analytics. The platform has already delivered groundbreaking results in early-access customer research collaborations with leading government, industry, and academic partners such as the United States Department of Defense (DoD), Sanofi, and Harvard Medical School.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its collaboration with VELL Health, a technology leader in wellness and holistic health, to introduce a groundbreaking holistic health and wellness application for people with Type 2 Diabetes in Guyana. This innovative initiative is part of Guyana’s nationwide pilot program for diabetes clinics which aims to improve healthcare by leveraging mobile technology, data sciences, and holistic health approaches.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that it has signed a collaborative agreement with Grupo Terralpe, Inc., a renowned private investment group based in Mexico City and Boston, Mass. Together, the companies will commercialize the pstateDx™ test, BPGbio’s prostate cancer diagnostic test, in Mexico.

Jun 28, 2023 | Kelsy Ketchum, 360Dx | NEW YORK – Artificial intelligence biopharmaceutical company BPGbio is validating a breast cancer…

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.